Objective: To observe the efficacy and tolerability of continuously infusing 5-fluorouracil (5-FU) / folic acid com- bined with oxaliplatin (L-OHP/5-FU/LV regimen) as first line treatment in advanced colorectal cancer...Objective: To observe the efficacy and tolerability of continuously infusing 5-fluorouracil (5-FU) / folic acid com- bined with oxaliplatin (L-OHP/5-FU/LV regimen) as first line treatment in advanced colorectal cancer. Methods: 23 patients of advanced colorectal cancer were treated with 5-FU 500 mg/d, civ, d1–d5, d8–d12, leucovorin 100 mg/d, iv gtt, d1, d8, folic acid tablet 60 mg/d, po, d2–d5, d9–d12, and oxaliplatin 65 mg/(m2?d), iv gtt, d1, d8, repeated every 21 days (one cycle).The effect was evaluated after two cycles. Results: Complete response in 2 cases and partial response in 10 cases were observed with an overall response rate of 47.18%. Adverse effects were mainly grade 1–2, including nausea, vomiting, diarrhea, dental ulcer, peripheral neuritis and myelosuppression. Conclusion: L-OHP/5-FU/LV regimen is an effective and better tolerated alterna- tive treatment in advanced colorectal cancer and yields promising clinical application.展开更多
背景与目的:CPT-11联合5-FU/CF(FOLFIRI)化疗方案是治疗晚期结直肠癌的有效方案。但是,该方案作为一线方案治疗中国晚期结直肠癌患者的资料缺乏,其疗效和安全性仍需进一步确定。本文旨在探讨FOLFIRI方案作为一线治疗方案对中国晚期结直...背景与目的:CPT-11联合5-FU/CF(FOLFIRI)化疗方案是治疗晚期结直肠癌的有效方案。但是,该方案作为一线方案治疗中国晚期结直肠癌患者的资料缺乏,其疗效和安全性仍需进一步确定。本文旨在探讨FOLFIRI方案作为一线治疗方案对中国晚期结直肠癌患者的疗效和安全性。方法:自2002年1月至2005年9月期间,共54例晚期结直肠癌患者采用FOLFIRI方案作为一线方案进行治疗,回顾性分析其治疗有效率(response rate,RR)、疾病进展时间(time to progression,TTP)、总生存时间(overall survival,OS)和不良反应。结果:54例患者中52例可评价疗效。其中RR为42.6%,TTP为6个月,OS为15.2个月。最常见的不良反应为中性粒细胞减少(38.9%)、腹泻(37.1%)和恶心呕吐(50.0%),Ⅲ/Ⅳ级的发生率分别为5.6%、9.3%和9.3%,总体耐受性好。结论:FOLFIRI方案治疗中国晚期结直肠癌患者疗效肯定,作为一线化疗方案有较高的有效性,不良反应可以耐受。展开更多
文摘Objective: To observe the efficacy and tolerability of continuously infusing 5-fluorouracil (5-FU) / folic acid com- bined with oxaliplatin (L-OHP/5-FU/LV regimen) as first line treatment in advanced colorectal cancer. Methods: 23 patients of advanced colorectal cancer were treated with 5-FU 500 mg/d, civ, d1–d5, d8–d12, leucovorin 100 mg/d, iv gtt, d1, d8, folic acid tablet 60 mg/d, po, d2–d5, d9–d12, and oxaliplatin 65 mg/(m2?d), iv gtt, d1, d8, repeated every 21 days (one cycle).The effect was evaluated after two cycles. Results: Complete response in 2 cases and partial response in 10 cases were observed with an overall response rate of 47.18%. Adverse effects were mainly grade 1–2, including nausea, vomiting, diarrhea, dental ulcer, peripheral neuritis and myelosuppression. Conclusion: L-OHP/5-FU/LV regimen is an effective and better tolerated alterna- tive treatment in advanced colorectal cancer and yields promising clinical application.
文摘背景与目的:CPT-11联合5-FU/CF(FOLFIRI)化疗方案是治疗晚期结直肠癌的有效方案。但是,该方案作为一线方案治疗中国晚期结直肠癌患者的资料缺乏,其疗效和安全性仍需进一步确定。本文旨在探讨FOLFIRI方案作为一线治疗方案对中国晚期结直肠癌患者的疗效和安全性。方法:自2002年1月至2005年9月期间,共54例晚期结直肠癌患者采用FOLFIRI方案作为一线方案进行治疗,回顾性分析其治疗有效率(response rate,RR)、疾病进展时间(time to progression,TTP)、总生存时间(overall survival,OS)和不良反应。结果:54例患者中52例可评价疗效。其中RR为42.6%,TTP为6个月,OS为15.2个月。最常见的不良反应为中性粒细胞减少(38.9%)、腹泻(37.1%)和恶心呕吐(50.0%),Ⅲ/Ⅳ级的发生率分别为5.6%、9.3%和9.3%,总体耐受性好。结论:FOLFIRI方案治疗中国晚期结直肠癌患者疗效肯定,作为一线化疗方案有较高的有效性,不良反应可以耐受。
